November-2014 Volume 10 Issue 5

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

"V体育官网入口" International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment. V体育安卓版.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology. VSports最新版本.

Experimental and Therapeutic Medicine (VSports手机版)

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine. V体育平台登录.

V体育官网 - Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

V体育官网入口 - Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-2014 Volume 10 Issue 5

Full Size Image

Article

Liraglutide ameliorates renal injury in streptozotocin‑induced diabetic rats by activating endothelial nitric oxide synthase activity via the downregulation of the nuclear factor‑κB pathway

Authors:
- Sai‑Jun Zhou
- Lian Bai
- Lin Lv
- Rui Chen
- Chun‑Jun Li
- Xiang‑Yang Liu
- De‑Min Yu
- Pei Yu
View Affiliations

Affiliations: Department of Diabetic Nephropathy Hemodialysis, 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Key Laboratory of Hormones and Development (Ministry of Health), Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300070, P.R. China
Published online on: September 10, 2014 https://doi.org/10.3892/mmr.2014.2555
Pages: 2587-2594

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Accumulating evidence has implicated that liraglutide, one of the human glucagon‑like peptide‑1 (GLP‑1) analogues, elicits protective effects on diabetic nephropathy; however, the mechanism has yet to be fully elucidated. The present study aimed to assess the effect and underlying mechanisms of liraglutide in diabetic nephropathy. Wistar rats with streptozotocin‑induced diabetes mellitus were subcutaneously injected with liraglutide or phosphate buffer for 12 weeks at a dose of 0.3 mg/kg/12 h. The biochemical parameters were determined, renal histological examination was performed by hematoxylin and eosin and periodic acid Schiff base staining, and the mRNA levels of nuclear factor κB (NF‑κB) and endothelial nitric oxide synthase (eNOS) were assessed by quantitative polymerase chain reaction. Furthermore, the protein expression of NF‑κB and eNOS as well as eNOS phosphorylation were examined by western blot analysis and the levels of inflammatory cytokines downstream of NF‑κB were evaluated by fluorescence-assisted cell sorting and finally, the eNOS activity and nitric oxide (NO) production were evaluated by ELISA. Liraglutide decreased the levels of total cholesterol, urine, 24-h urinary albumin, blood urea nitrogen, serum creatinine and histological damage. Liraglutide also reduced the expression of NF‑κB at mRNA and protein levels; the expression of tumor necrosis factor‑α, interferon‑γ, interleukin‑6 and monocyte chemoattractant protein‑1 were also reduced. By contrast, eNOS phosphorylation, eNOS activity and NO production appeared to have increased. Liraglutide may have a direct beneficial effect on diabetic nephropathy by improving eNOS activity by inhibiting the NF‑κB pathway without eliciting a glucose lowering effect.

View Figures

View References

1	Nakagawa T: Is endothelial dysfunction more deleterious than podocyte injury in diabetic nephropathy. Kidney Int. 83:1202–1203. 2013. View Article : Google Scholar VSports最新版本.
2	Nakagawa T, Sato W, Sautin YY, et al: Uncoupling of vascular endothelial growth factor with nitric oxide as a mechanism for diabetic vasculopathy. J Am Soc Nephrol. 17:736–745 V体育平台登录. 2006. View Article : Google Scholar : PubMed/NCBI.
3	Nakagawa T, Sato W, Glushakova O, et al: Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy VSports注册入口. J Am Soc Nephrol. 18:539–550. 2007. View Article : Google Scholar : PubMed/NCBI.
4	Tian S, Gan Y, Li J, et al: Imbalance of glomerular VEGF-NO axis in diabetic rats: prevention by chronic therapy with propyl gallate. J Nephrol V体育官网入口. 24:499–506. 2011. View Article : Google Scholar : PubMed/NCBI.
5	Chiu WC, Chiou TJ and Chiang AN: β-Glycoprotein I inhibits endothelial cell migration through the nuclear factor κB signalling pathway and endothelial nitric oxide synthase activation. Biochem J VSports在线直播. 445:125–133. 2012.
6	Kim JE, Lee MH, Nam DH, et al: Celastrol, an NF-κB inhibitor, improves insulin resistance and attenuates renal injury in db/db mice V体育2025版. PLoS One. 8:e620682013.
7	Shiraki A, Oyama J, Komoda H, et al: The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis VSports. 221:375–382. 2012. PubMed/NCBI.
8	Parthsarathy V and Hölscher C: The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain. Eur J Pharmacol. 700:42–50. 2013. View Article : Google Scholar : PubMed/NCBI
9	Hendarto H, Inoguchi T, Maeda Y, et al: GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism. 61:1422–1434. 2012. View Article : Google Scholar
10	Sturis J, Gotfredse CF, Rømer J, et al: GLP-1 derivative liraglutide in rats with β-cell deficiencies: influence of metabolic state on β-cell mass dynamics. British J Pharmacol. 140:123–132. 2003.
11	Shiju TM, Rajesh NG and Viswanathan P: Renoprotective effect of aged garlic extract in streptozotocin-induced diabetic rats. Indian J Pharmacol. 45:18–23. 2013. View Article : Google Scholar : PubMed/NCBI
12	Hill HR and Martins TB: The flow cytometric analysis of cytokines using multi-analyte fluorescence microarray technology. Methods. 38:312–316. 2006. View Article : Google Scholar : PubMed/NCBI
13	Rigato M and Fadini GP: Comparative effectiveness of liraglutide in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes. 7:107–120. 2014.PubMed/NCBI
14	Vretenar J, Jindal K and Senior PA: Effect of liraglutide on metabolic and renal outcomes over 12 months in community diabetic nephropathy clinics. Can J Diabetes O. 37S4:S252013. View Article : Google Scholar
15	García C, Nuñez-Anita RE, Thebault S, et al: Requirement of phosphorylatable endothelial nitric oxide synthase at Ser-1177 for vasoinhibin-mediated inhibition of endothelial cell migration and proliferation in vitro. Endocrine. 45:263–270. 2013.PubMed/NCBI
16	Parthsarathy V and Hölscher C: The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain. Eur J Pharmacol. 700:42–50. 2013. View Article : Google Scholar : PubMed/NCBI
17	Xie X, Lan T, Chang X, et al: Connexin43 mediates NF-κB signalling activation induced by high glucose in GMCs: involvement of c-Src. Cell Commun Signal. 11:382013.PubMed/NCBI
18	Okazaki T, Sakon S, Sasazuki T, et al: Phosphorylation of serine 276 is essential for p65 NF-kappaB subunit-dependent cellular responses. Biochem Biophys Res Commun. 300:807–812. 2003. View Article : Google Scholar : PubMed/NCBI
19	Wang M, Liu R, Jia X, Mu S and Xie R: N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal inflammation and tubulointerstitial fibrosis in rats. Int J Mol Med. 26:795–801. 2010.PubMed/NCBI
20	Jain SK, Velusamy T, Croad JL, Rains JL and Bull R: L-cysteine supplementation lowers blood glucose, glycated hemoglobin, CRP, MCP-1, and oxidative stress and inhibits NF-kappaB activation in the livers of Zucker diabetic rats. Free Radical Bio Med. 46:1633–1638. 2009. View Article : Google Scholar
21	Wada J and Makino H: Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond). 124:139–152. 2013. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

"V体育官网入口" International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine (VSports手机版)

V体育官网 - Oncology Letters

Biomedical Reports

V体育官网入口 - Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Liraglutide ameliorates renal injury in streptozotocin‑induced diabetic rats by activating endothelial nitric oxide synthase activity via the downregulation of the nuclear factor‑κB pathway

This article is mentioned in:

Abstract

"V体育官网" Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Related Articles